mRECIST for systemic therapies: More evidence is required before recommendations can be made
- PMID: 28315710
- DOI: 10.1016/j.jhep.2017.02.033
mRECIST for systemic therapies: More evidence is required before recommendations can be made
Comment in
-
Reply to: "mRECIST for systemic therapies: More evidence is required before recommendations could be made".J Hepatol. 2017 Jul;67(1):196-197. doi: 10.1016/j.jhep.2017.03.004. Epub 2017 Mar 16. J Hepatol. 2017. PMID: 28315709 No abstract available.
Comment on
-
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.J Hepatol. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26. J Hepatol. 2017. PMID: 28131794 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
